Skip to main content
Apellis Pharmaceuticals, Inc. logo

Apellis Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · APLS ISIN · US03753U1060 LEI · 254900HS0ZFRXXSB9D42 US Manufacturing
Open in API
Filings indexed 1,129 across all filing types
Latest filing 2020-02-27 Share Issue/Capital Cha…
Country US United States of America
Listing US APLS

About Apellis Pharmaceuticals, Inc.

https://apellis.com/

Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company focused on developing therapies for a broad range of debilitating diseases by targeting the complement cascade. The company's scientific approach is centered on controlling C3, a central protein in this part of the immune system, to treat conditions driven by its overactivation. Apellis's development efforts are concentrated in the areas of ophthalmology, hematology, and nephrology. Its portfolio of approved medicines includes SYFOVRE® (pegcetacoplan injection) for the treatment of geographic atrophy (GA) and EMPAVELI® (pegcetacoplan) for other serious, complement-driven diseases.

Recent filings

Filing Released Lang Actions
S-8
Share Issue/Capital Change Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by Apellis Pharmaceuticals, Inc. It registers shares of common stock under the 2017 Stock Incentive Plan and inducement stock option awards. The document includes detailed information about the securities to be registered, calculation of registration fees, incorporation by reference of prior filings, and indemnification provisions for directors and officers. Form S-8 is a registration statement used for securities issued under employee benefit plans and inducement awards, which is a type of capital raising or share issuance activity. This aligns with the category for announcements regarding new share issues or capital changes. Therefore, the document is best classified as a Share Issue/Capital Change filing.
2020-02-27 English
10-K
Annual Report FY 2019
2020-02-27 English
PRIMARY DOCUMENT
Director's Dealing
2020-02-20 English
PRIMARY DOCUMENT
Director's Dealing
2020-02-19 English
PRIMARY DOCUMENT
Director's Dealing
2020-02-14 English
APELLIS PHARMACEUTICALS, INC.
Major Shareholding Notification
2020-02-14 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.